Single-center, Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells) in Healthy People Aged 6-17 Years

JSVCT125

This is a phase Ⅰ/Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the safety, tolerability and immunogenicity of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy aged 6-17 years with immunization procedures 0, 21, 42 days and doses (10μg/20μg/40μg).

2024-07-01

2024-12-01

2025-12-01

Not yet recruiting

Early phase I

600

Inclusion Criteria: * Aged 6-17 years； * The subject and/or guardian can understand and voluntarily sign the informed consent form (double signature is required for 8-17 years old)； * Reproductive women have a negative pregnancy test before each vaccination； * The subjects are able and willing to comply with the requirements of the clinical trial protocol, and can complete the study follow-up for approximately 13.5 months. Exclusion Criteria: * History of SARS-CoV-2 infection. * The COVID-19 antibody (IgG and IgM) screening was positive. * History of asthma, history of allergy to vaccines or vaccine components, or severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioedema. * Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * Autoimmune diseases or immunodeficiency/immunosuppression. * Severe chronic diseases that cannot be controlled by drugs, severe cardiovascular diseases, diabetes, liver and kidney diseases, malignant tumors, etc. * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness. * Any condition caused by thyroid disease or history of thyroidectomy, hypersplenism, or splenectomy. * Diagnosis of abnormal blood clotting function (for example, lack of clotting factors, coagulopathy, abnormal platelets) or obvious bruising or blood clotting. * In the past 6 months, received immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and superficial corticosteroid therapy for acute uncomplicated dermatitis). * Laboratory test results with clinically significant abnormalities (severity level 2 and above) (applicable to phase I clinical trials only). * Received blood products in the last 3 months. * Receive other study drugs or vaccines within the past 30 days. * Vaccination against live attenuated vaccines in the past 30 days. * Inactivated vaccine or subunit vaccine in the past 14 days. * Acute disease or acute exacerbation of chronic disease in the last 7 days. * Axillary temperature\> 37.0°C. * According to the judgment of the investigator, the subject has other factors that are not suitable for participating in the clinical trial. Subsequent dose exclusion criteria: In this trial, the second/third dose of vaccination may be stopped in some cases. This includes allergic reactions, severe hypersensitivity reactions, or grade 3 or higher adverse reactions that cannot be tolerated after previous vaccination/placebo. If these reactions occur, the subject should not continue to receive the second/third vaccination.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 600, 'type': 'ESTIMATED'}}

2024-04-24